Management of Diabetes in Decompensated Liver Disease

Introduction to Diabetes Management

The European Association for the Study of the Liver recommends insulin therapy as the only evidence-based option for treating diabetes in patients with decompensated cirrhosis and should be used as first-line treatment 1, 2, 3

Insulin therapy should be initiated in a hospital setting due to high variations in glucose levels and risks of hypoglycemia, which may be confused with hepatic encephalopathy 1, 2
Careful supervision is required when administering insulin to avoid precipitating hypoglycemia and metabolic encephalopathy 1
Optimal fasting blood glucose levels should not exceed 10 mmol/L (180 mg/dL) to avoid hyperglycemic complications 1, 3

Metformin is contraindicated in decompensated cirrhosis due to increased risk of lactic acidosis, especially when there is concomitant renal impairment 4, 5, 6
Sulfonylureas should be avoided in patients with hepatic decompensation because of the increased risk of hypoglycemia 5, 6

GLP-1 receptor agonists can be used only in Child-Pugh class A (compensated) cirrhosis 5, 6, 3
SGLT2 inhibitors can be used in Child-Pugh class A and B cirrhosis but not in decompensated cirrhosis 5, 6, 3

HbA1c should not be used for diagnosis or monitoring of diabetes in decompensated cirrhosis due to altered red blood cell turnover 1, 3
Monitor for hypoglycemia vigilantly, as symptoms may be confused with hepatic encephalopathy 1, 2

Poor nutritional status is common in decompensated cirrhosis and contraindicates hypocaloric diets 1
A high-protein diet (1.2-1.5 g/kg body weight/day) and a late-evening snack are recommended for patients with sarcopenia or decompensated cirrhosis 5, 6, 3
Aim for at least 35 kcal/kg of body weight/day to maintain adequate nutrition 6

Failure to recognize that hypoglycemic symptoms may mimic hepatic encephalopathy, leading to diagnostic confusion 1, 2
Overaggressive glycemic control may increase hypoglycemia risk in an already vulnerable population 1, 3
Inadequate consideration of renal function, which is often impaired in decompensated cirrhosis and affects medication clearance 2

Insulin analogs are the preferred insulin formulation when insulin therapy is required in patients with compensated cirrhosis, offering flatter basal profiles and more predictable prandial coverage compared to NPH and regular human insulin 7
Long-acting basal analogs (U-300 glargine or degludec) confer lower hypoglycemia risk compared to U-100 glargine or NPH insulin in patients with cirrhosis 7
Rapid-acting analogs for prandial coverage are faster-acting and provide better postprandial glucose control than regular human insulin in patients with cirrhosis 7, 8

Alternative agents (GLP-1 receptor agonists, SGLT2 inhibitors, metformin with GFR >30 ml/min) may be considered before requiring insulin in patients with compensated cirrhosis 9, 10
Insulin is the only evidence-based treatment option and must be initiated in a hospital setting for patients with decompensated cirrhosis due to extreme glucose variability and high hypoglycemia risk 9

Metformin is absolutely contraindicated due to lactic acidosis risk, especially with concomitant renal impairment in patients with decompensated cirrhosis 9, 10
Sulfonylureas must be avoided due to severe hypoglycemia risk in patients with decompensated cirrhosis 10
GLP-1 receptor agonists and SGLT2 inhibitors should not be used in decompensated cirrhosis 9, 10

Start with basal insulin analog at 10 units or 0.1-0.2 units/kg body weight for patients with cirrhosis 11
Typical total daily insulin requirements range from 0.4-1.0 units/kg/day, with approximately 50% as basal and 50% as prandial for patients with cirrhosis 7

Maintain adequate nutrition with at least 35 kcal/kg body weight/day for patients with cirrhosis 10
Provide high-protein diet (1.2-1.5 g/kg/day) to prevent sarcopenia in patients with cirrhosis 10

Using human insulins (NPH, regular) when analogs are available, missing the opportunity for improved safety profiles in patients with cirrhosis 7
Continuing metformin or sulfonylureas in decompensated cirrhosis is contraindicated 10